Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a commercial-stage oncology company with a core focus on developing novel kinase inhibitors using its proprietary switch-control platform. Its achievements include the 2020 FDA approval of QINLOCK for advanced GIST and the 2025 approval of ROMVIMZA for TGCT, solidifying its transition to a commercial entity. Following its 2024 acquisition by Japan's ONO Pharmaceutical, Deciphera now operates as a key U.S./European subsidiary, leveraging enhanced resources to advance a robust, diversified pipeline. The company's strategy centers on overcoming drug resistance in cancer and expanding into new therapeutic areas through internal R&D and strategic collaboration.

Proprietary switch-control kinase inhibitor platform designed to stabilize kinases in their inactive conformation, aiming to provide broad inhibition of mutation states and overcome drug resistance.